Details:
Under the partnership, Quotient will support Crinetics' CRN04894 pediatric program. The partnership will utilize Quotient Sciences' unique Translational Pharmaceutics® platform to provide integrated formulation development, clinical manufacturing, and taste assessment studies.
Lead Product(s): CRN04894
Therapeutic Area: Endocrinology Product Name: CRN04894
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Crinetics Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 30, 2023
Details:
The combined company will focus on the clinical development of pipeline candidates ZB-168 and torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways.
Lead Product(s): ZB-168
Therapeutic Area: Endocrinology Product Name: ZB-168
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: JATT Acquisition
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 21, 2023
Details:
AT247 (ultra rapid acting prandial insulin aspart) has the potential to significantly improve blood glucose control when delivered via insulin pump and is an important step in enabling the development of a fully closed loop/artificial pancreas system for people with diabetes.
Lead Product(s): Ultra Rapid Acting Prandial Insulin Aspart
Therapeutic Area: Endocrinology Product Name: AT247
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
Data from Phase I clinical trial of AT278 (Ultra-Concentrated Rapid Acting Insulin Aspart), showed that it exhibited an accelerated PK and PD profile when compared to NovoRapid®, a gold standard prandial insulin treatment, despite a 5-fold increase in concentration.
Lead Product(s): Ultra-Concentrated Rapid Acting Insulin Aspart
Therapeutic Area: Endocrinology Product Name: AT278
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
PK/PD profile for AT278 was accelerated compared with NovoRapid. Following dosing, AT278 showed faster onset of insulin exposure compared with NovoRapid, demonstrated by an earlier onset of appearance, also showed rapid onset of glucose-lowering effect compared with NovoRapid.
Lead Product(s): Ultra-Concentrated Rapid Acting Insulin Aspart
Therapeutic Area: Endocrinology Product Name: AT278
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
AT278, is an ultra-concentrated novel formulation of insulin, that has been designed to significantly accelerate insulin absorption post injection to enable more effective and convenient management of blood glucose levels in people with high daily insulin requirements.
Lead Product(s): Ultra-Concentrated Rapid Acting Insulin Aspart
Therapeutic Area: Endocrinology Product Name: AT278
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
AT247 is an ultra-rapid insulin that aims to accelerate insulin absorption, post injection, to enable more effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes.
Lead Product(s): Insulin aspart
Therapeutic Area: Endocrinology Product Name: AT247
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2022
Details:
First patient dosed in potential game-changing diabetes combination therapy of AT247 (Ultra-rapid Insulin), exhibited an earlier insulin appearance, exposure, and offset, with corresponding enhanced early glucose-lowering effect compared with NovoRapid® and Fiasp®.
Lead Product(s): Ultra-rapid Acting insulin Aspart,Rapid Acting Insulin Aspart,Fast Acting Insulin Aspart
Therapeutic Area: Endocrinology Product Name: AT247
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
Details:
AT278 is a novel proprietary formulation of concentrated insulin (500U/mL) that is designed to maintain rapid-acting characteristics in a reduced volume, thereby enabling fast absorption into the bloodstream from the site of injection.
Lead Product(s): Ultra-concentrated Rapid Acting Insulin Aspart
Therapeutic Area: Endocrinology Product Name: AT278
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
The presesntation will highlight data from company's Phase I study investigating the PD, PK and safety of AT247 in comparison with NovoRapid® and Fiasp.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020